Octapharma USA lures Pfizer exec to its marketing team
Swiss family-owned protein specialist Octapharma has appointed pharmaceutical industry veteran Kelly Hearn as vice president of commercial development and marketing of its American company, Octapharma USA.
Ms Hearn will take immediate leadership of the product marketing team as the company continues to grow its presence in the US market.
“Kelly Hearn brings to Octapharma USA an entrepreneurial spirit and a passion for developing and launching novel products to market that improve patient health outcomes,” said Octapharma USA president Flemming Nielsen. “During more than 20 years with Pfizer, Kelly has demonstrated impressive abilities to drive strategic expansion as well as operational excellence and transformation. We are pleased to welcome Kelly to our senior leadership team and look forward to her continued success,” he noted.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze